Hepatitis B Genotypes in Iran

Mohammad Reza Haghshenas, Mohsen Arabi, Tahoora Mousavi

Molecular Cell-Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Corresponding author: Tahoora Mousavi, Molecular Cell-Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran Phone NO:+989112545144 Tahoora_Mousavi@yahoo.com

ABSTRACT
Hepatitis B virus (HBV) infection is a public health problem as a cause of liver diseases including hepatocellular carcinoma and cirrhosis. It is estimated that 350 million people live with chronic infection and about one million people die every year from complication of this chronic disease in the world. So far, ten HBV genotypes (A-J) has been identified which show a geographical distribution. Throughout the world, carrier variability rate for hepatitis B infection is estimated to be 0.1% to 20%, with regions classified as having low endemcity (<2%), intermediate endemcity (2-7%) and high endemcity (>8%). The prevalence of hepatitis B infection is estimated at 2 to 7 percent In Iran. After HBV vaccination program the prevalence of hepatitis B infection has been reported less than 2%, so Iran can be considered one of the countries with low HBV infection endemcity. In Iran several studies were shown that the only genotype of HBV(100%)was found genotype D as the prominent type in some provinces, but some studies reported genotype B(5%)as well as genotype D(95%).The distribution of HBV genotypes may guide us in determining disease burden, prognosis and antiviral responses. So, it is important to know the epidemiologically of HBV genotyping as well.

Key words: HBV, hepatocellular carcinoma, cirrhosis.

1. INTRODUCTION
Hepatitis B virus is one of the most important factors for infected diseases in the world. It was estimated that 350 million people infected with hepatitis B virus and almost 75% patients are living in Asia (1). Nearly one million people die annually from chronic liver diseases such as, chronic hepatitis B, cirrhosis and hepatocellular carcinoma (2).

The prevalence of hepatitis B is reported various in different parts of the world, so this virus existed as hyper endemic in most Asian countries. Throughout the world, carrier variability rate for hepatitis B infection is estimated to be 0.1% to 20% which is different in various areas and is classified into three regions: the first group with areas as having low (<2%), the second group with intermediate prevalence (2-7%) and with high prevalence (>8%) (3). The prevalence of hepatitis B infection is high in Africa, Southeast Asia, the middle East, southern and western pacific island. (they are of endemic regions) Intermediate areas consist of south central and southwest Asia, Israel, Japan, Eastern, Southern Europe and Russia and prevalence of hepatitis B infection is low in Northern and Western Europe, North America, Australia, New Zealand, Mexico and southern America (4).

In Iran, a study showed that 35% of population were infected with hepatitis B and the percentage of chronic carriers is about 3%; although after implementing control programs and public vaccination, the prevalence of HBV infection has reduced to less than 2% (5).

The HBV has ten genotypes (A-J) ,multiple subtypes and se-rotypes (adr, adw, ayr, ayw), showing genotypes vary in different geographic areas worldwide. There is a relation between serotype and genotype in the world (6). It seems that infected persons with different genotypes show various responses to therapy (7). Also different in genotypes have shown influences in sever course of disease, infection and vaccination (8). Some studies suggested that genotype D could increase the risk of cirrhosis than genotype C(9), on the other hand some evidences showed no difference between these types in infection risk to HCC(10). Moreover some researches found that genotype A is more associated with higher risk of HCC than genotype D(11). Recent study showed that genotype C was more strongly associated with HCC than infected patients with genotypes A, B and D (12). Pre-core stop codon and basal core promoter mutations are of another difference in risk of HCC in various HBV genotypes. Pre-core stop codon A1896 is less in genotype C than genotype B. Basal core promoter mutations in X gene upstream of pre-core area is more in genotypes C (13). This mutation increases the risk of HCC in patients with chronic hepatitis (14). HBV genotypes have different distinguished biological and are able to influence the expression of antigen and immune functional, so recognizing HBV genotypes is important in a country.

This article has investigated the HBV genotyping and was carried out Iran based on papers that identified HBV genotype in Iranian population published in English and Persian languages.

2. HBV MUTANTS
The HBV belongs to hepadnaviridae family. This genome of HBV includes circular DNA that some part of it is bi-string and contains reverse transaction enzyme and/or polymerase DNA.
Full string genome contains 3020-3320 nucleotides and short length strand is 1700-2800 nucleotides. There are four areas encoded by HBV genome C, X, P, S. Some mutants have found in hepatitis B. In many of this, mutation in pre-core genome is associated with inactivation of HBcAg (YMDD, S mutant) (15).

In patients, this mutant is associated with severity of disease and less response to therapy (16). YMDD region in virus polymerase is located in places influenced by most of reverse transcriptase inhibitor such as Lamivudine and lamivudine thus, after one year therapy with lamivudine, nearly 24% of patients have showed YMDD mutations (17). The most common core promoter includes the relocation between 1762 and 1764 nucleotides (18). Many of pre-core mutations are related to G-A changing in the 1896 nucleotide, causing the stop codon and preventing the functional of HBcAg genome.

A study has reported that 58% of infections are the type of pre-core infection in Iran (19). Negative HBcAg carriers have been heterogeneous; most of them have had less DNA level and normal alanintransferase; so they could not be able to completely respond to therapy. Some evidences showed that 15-20 of HBcAg carriers have a high level of ALT and HBV DNA in Mediterranean, Eastern Asia and Southern Europe (20).

### 3. GEOGRAPHICAL PREVALENCE HBV GENOTYPES IN THE WORLD

Genotype A is divided into two sub-genotypes Aa (A1), Ae(A2). Sub-genotype Aa (A1) was found in Africa/Asia and Philippine. Sub-genotype Ae(A2) was more common in Europe/united state. Genotype B is also divided into two sub genotype Ba/B2 (Asia) and Bj/B2 (j-Japan) and the prevalence of them has been reported in different areas. Ba has classified to four class B2-B4, these sub genotypes have more virulence than Bj (21).

Genotype C contains five sub genotype (C1-C6). Variation of nucleotide between C1, C2 is 5/2%. C5 (C1) is more common in south east of Asia and Ce (C2) was observed in Japan, China, Korea, east of Asia (22). C3 was reported in Polynesia, Caledonia areas and C4 was detected in Australia, and C5 and C6 were found in Philippine (23). Genotype C, is associated with hepatocellular carcinoma in Japanese patients and it was not found in Taiwanese patients less than 50 years of age (24). The prevalence of C-1858 strains was found in Southeast Asia (25). In addition, several phylogenetic locations for genotype C isolations were observed. Genotype D is divided into seven sub-genotype (D1-D2) which are prevalent in Pakistan, India, Afghanistan, Mediterranean areas (26). Studies show that sub genotypes D1 and D2 were found in Turkey (27) but sub genotype D3 was observed more in Asia (East India), south of Africa and Europe and sub genotype D4 was identified in Australia (28). Recently sub genotype D5 has been reported in east of India and Japan (29). A study suggested that genotype D and serotype ayw2 with 94/4% are predominant in HBV positive in Iran (30).

Genotype E is limited to sub-Saharan Africa. Genotype F has been divided into four sub genotype (F1-F4), also sub genotype F1 was classified to two sub genotype 1a, 1b. Sub-genotypes F2, F1 were observed in Venezuela and sub genotype F3 was found in east and west of America. F3 is the only predominant sub genotype in south of America. Some evidences showed that sub genotype 1a from F1 is derived from center of America, sub genotype F3 is found in north of America and sub genotype F4 had been identified from South of America, but sub genotypes of 1b from F2 is prevalent in most of United states instead of north of southern America and north of America (31).

Genotype F is predominant in Brazil and genotype G is reported in France and united state; also 4-8% difference in subtypes of genotype E and F has been reported (32). Genotype H is limited to center of America, Mexico and California (33).

Figure 1 illustrates the prevalence of HBV genotypes in the world (32). It has been reported that genotype I was found in north east of India and genotype J was detected in Japanese patients (33).

There are some significant differences in clinical characteristics and virology of infected patients with various genotypes. It seems that different genotypes may have different responses to therapy (8).

### 4. EPIDEMIOLOGY OF SEROTYPES AND GENOTYPES OF HBV IN IRAN

In this study we found 22 studies that were discussed about serotypes and genotypes of HBV in Iran. In six studies, serotype ayw2 was reported as the predominant serotype with relatively abundance more than 94% (Table 1).

The first study about genotypes of HBV was done in 2005 in Iran and genotype D is defined as predominant genotype in Iran (Table 2).

<table>
<thead>
<tr>
<th>Serotype</th>
<th>Diagnostic Method</th>
<th>Type of sample</th>
<th>Year</th>
<th>Location</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ayw2 (94.4%)</td>
<td>PCR</td>
<td>280 blood samples with HBV infection</td>
<td>2008</td>
<td>5 province of Iran</td>
<td>Mohabbi, et al (36)</td>
</tr>
<tr>
<td>ayw1 (2.8%), ayw3 (2%)</td>
<td>PCR</td>
<td>5 Iranian chronic HBV carriers</td>
<td>2005</td>
<td>Tehran</td>
<td>Aminia-Bazv-Olyaei et al (37)</td>
</tr>
<tr>
<td>ayw4 (0.4%)</td>
<td>PCR</td>
<td>100 patients with proved HBV infection</td>
<td>2012</td>
<td>Golestan</td>
<td>Moradi, et al (38)</td>
</tr>
<tr>
<td>ayw2 (100%)</td>
<td>Real time</td>
<td>60 HBV-positive blood donors</td>
<td>2009</td>
<td>Shahrekord</td>
<td>Doosti, et al (39)</td>
</tr>
<tr>
<td>ayw1 (94%)</td>
<td>PCR</td>
<td>170 asymptomatic HbsAg positive blood donors</td>
<td>2011</td>
<td>Iran</td>
<td>Garimiri, etal (40)</td>
</tr>
<tr>
<td>ayw2 (100%)</td>
<td>PCR</td>
<td>46 patients with chronic HBV infection</td>
<td>2012</td>
<td>Kermanshah</td>
<td>Sayad, et al (41)</td>
</tr>
</tbody>
</table>

**Table 1. Prevalence of HBV’ serotype in Iran.**
Hepatitis B Genotypes in Iran

5. DISCUSSION

In this article, 22 studies were discussed about serotypes and genotypes of HBV in Iran. The results of these studies indicate that the predominant genotype and serotype in Iran is D and ayw2, respectively.

In other studies, there is genotype D in South Asia and East Asia, such as Iran, Afghanistan and India (57). This genotype was found the oldest type widely spread in the world. Also, addition to ancient civilization, evolving a special genotype for HBV seems that genotype D patients have been infected with virus before migration and caused to spread it. Therefore, in Iran, India and most of European countries, genotype D is seemingly prevalent (63).

Besides the old civilization; a specific genotype is showing the evaluation of HBV. HBV genotypes show different geographic distribution in the world. Genotype B is predominant in southern Japan (Okinawa) (64); while genotype C has been reported as the dominant type in mainland Japan (65). In various areas of Japan, this difference is related to the heterogeneity between ethnic relations (66). These relations suggests that human factors and racial is more important than geographical factors. HBV genotypes may derive from Europe in Asian countries like the case of India.

Genetic studies of mitochondrial DNA and Y chromosome in Indian population indicates the integration of immigrants gene from European countries and in northern parts is more than of South India (67). Another study showing the prevalence of HBV genotype and changing geographical; so that genotype D is more prevalent in west India. That genotype D3 are originated from the countries of Europe (61). Genetically research DNA mitochondria chromosome Y in Indians showed the integration of migrants’ genotypes from Europe countries that defines in the northern area more than India (62). Other studies have showed that abundance of genotype HBV can be the reflection of geographical Close relation among this transformation. Genotype D is the oldest type that has spread widely in the world (Nicobar and Andaman Islands). Also, there are genotypes A and D in the north of India and much more probably it is due to migration from Europe which resulted in high prevalence of genotype D in most parts of India. In Iran, it can be deduced that Aryans was first habitants of Caspian sea, then migrated to the other areas of India and Europe. It is possible that some persons infected with genotype D were infected before migration and caused to spread it.

6. CONCLUSION

Because HBV genotypes show distinct geographical distribution, genotype D is predominant in Iran. Despite the different geographical areas in different parts of Iran, genotype D is considered as the predominant genotype. With regard to surveillance, hepatitis in Iranian health system, defining sequences among different isolates of HBV by appropriate intervals or disease outbreaks can be effective in explaining differences in clinical treatment and response to treatment. Also, knowing
infection to HBV genotypes can help in the standardization of treatment interference and selection of proper regimens for this disease.

Conflict of interest: none declared.

REFERENCES


Hepatitis B Genotypes in Iran

Mater Sociomet. 2014 Apr; 26(2): 129-133 • PROFESSIONAL PAPER

133